Compare Regeneron Pharmaceuticals Inc (REGN) vs T-Mobile Us Inc (TMUS) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Regeneron Pharmaceuticals Inc vs T-Mobile Us Inc — how do they compare? Regeneron Pharmaceuticals Inc trades at $746.54 (market cap $76.14B), while T-Mobile Us Inc trades at $148.58 (market cap $183.76B). The key difference: T-Mobile Us Inc is far larger — about 2.4× Regeneron Pharmaceuticals Inc's market cap, and T-Mobile Us Inc pays the higher dividend (2.73%). Which is the better fit depends on your goals — on Pluang, investors hold Regeneron Pharmaceuticals Inc for 107 Days and T-Mobile Us Inc for 84 Days on average.
| REGN | TMUS | |
|---|---|---|
Market Cap | $76.14B | $183.76B |
Volume | 500,239 | 4,294,650 |
Sector | Health | Media |
52-Week High | $852.03 | $230.06 |
52-Week Low | $557.73 | $148.58 |
Typical Hold Time | 107 Days | 84 Days |
Enterprise Value | $70.85B | $300.37B |
Dividend Yield | 0.51% | 2.73% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Regeneron Pharmaceuticals (REGN) trades at $739.57, down 0.34% with a bearish technical signal. The company maintains strong fundamentals with a 27.86% net income margin and consistent earnings beats. Recent news highlights a significant $8 billion immunology alliance expansion with Sanofi, providing substantial upfront payments and milestone potential. Cash flow improved significantly in 2025 with $635 million net cash flow versus negative flows in prior years.
The stock presents a compelling investment case with strong profitability, positive analyst sentiment (69% buy ratings), and a $849.84 consensus price target offering 15% upside. Key risks include competitive pressures in ophthalmology drugs and reliance on key partnerships. The expanded Sanofi collaboration and promising clinical pipeline provide catalysts for growth.
TMUS trades at $171.31, up 2.2% today, with a bullish technical signal and strong earnings beats in recent quarters. Revenue grew to $88.31B in 2025, with a net income margin of 11.45%, while the company announced a 15% dividend hike and AI-driven 5G network enhancements. Analyst consensus is strongly bullish with a $231.10 price target, though debt levels and competitive pressures remain considerations.
The outlook for TMUS is positive, driven by robust cash flow, strategic investments in network resilience, and favorable analyst sentiment. Key risks include high debt exposure and industry competition, but strong fundamentals and growth initiatives support a constructive view for long-term investors.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Regeneron Pharmaceuticals Inc
Regeneron Pharmaceuticals discovers, develops, and commercializes products that fight eye disease, cardiovascular disease, cancer, and inflammation. The company has several marketed products, including Eylea, approved for wet age-related macular degeneration and other eye diseases
Read more on REGN →About T-Mobile Us Inc
Deutsche Telekom merged its T-Mobile USA unit with prepaid specialist MetroPCS in 2013, creating T-Mobile Us. Following the merger, the firm provided nationwide service in major markets but spottier coverage elsewhere. T-Mobile spent aggressively on low-frequency spectrum, well suited to broad coverage, and has substantially expanded its geographic footprint. This expansion, coupled with aggressive marketing and innovative offerings, produced rapid customer growth. With the Sprint acquisition, the firm's scale now roughly matches its larger rivals: T-Mobile now serves 71 million postpaid and 21 million prepaid phone customers, equal to around 30% of the U.S. retail wireless market. In addition, the firm provides wholesale service to resellers.
Read more on TMUS →
